Education
About Us
Working with TipRanks
Follow Us
Guard Therapeutics International AB (SE:GUARD)
:GUARD
RESEARCH TOOLSreports
GUARD Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr11.85 - kr33.37
Previous CloseN/A
Volume1.94K
Average Volume (3M)25.72K
Market Cap
kr411.42M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-1.12
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding20,167,631
10 Day Avg. Volume28,634
30 Day Avg. Volume25,717
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr11.85 and its highest was kr33.37 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr411.42M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 21, 2025 which is in 20 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 05, 2025. The company reported -kr2.783 earnings per share for the quarter, missing the consensus estimate of N/A by -kr2.783.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr2.783 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.818%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Oncopeptides AB
―
Xbrane Biopharma AB
―
Intervacc AB
―
Immunicum AB
―
Cantargia AB
―